- Report
- October 2024
- 190 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- March 2025
- 196 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- March 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- September 2024
- 135 Pages
Global
From €2862EUR$2,999USD£2,398GBP
- Report
- January 2025
- 140 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- February 2025
- 184 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- July 2024
- 150 Pages
Global
From €3579EUR$3,750USD£2,999GBP
- Report
- January 2025
- 187 Pages
Global
From €4767EUR$4,995USD£3,994GBP
- Report
- August 2023
- 336 Pages
Global
From €4438EUR$4,650USD£3,718GBP
- Report
- July 2023
- 230 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- April 2021
Global
From €859EUR$900USD£720GBP
- Report
- October 2023
- 190 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- February 2024
- 176 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 85 Pages
North America
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 100 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- August 2020
- 150 Pages
Global
From €4056EUR$4,250USD£3,398GBP
- Report
- March 2019
- 90 Pages
Europe
From €4533EUR$4,750USD£3,798GBP
- Report
- May 2018
- 106 Pages
Global
From €3340EUR$3,500USD£2,799GBP
- Drug Pipelines
- December 2022
- 148 Pages
Global
From €14311EUR$14,995USD£11,991GBP

The Oral Insulin market is a subset of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs that are taken orally to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Oral Insulin is a relatively new form of treatment, and is seen as a more convenient and less invasive alternative to traditional insulin injections. It is also seen as a potential solution to the problem of poor adherence to insulin therapy.
Oral Insulin is still in the early stages of development, and there are currently no approved oral insulin products on the market. However, several companies are researching and developing oral insulin products, and some have already completed clinical trials. Companies in the Oral Insulin market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Pfizer. Show Less Read more